Cogent Biosciences, Inc. (COGT)
34.67
-2.42
(-6.52%)
USD |
NASDAQ |
Aug 28, 16:00
34.73
+0.06
(+0.17%)
After-Hours: 20:00
Cogent Biosciences Cash from Operations (Quarterly) : -77.27M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -77.27M |
| March 31, 2026 | -86.88M |
| December 31, 2025 | -79.10M |
| September 30, 2025 | -64.29M |
| June 30, 2025 | -54.54M |
| March 31, 2025 | -66.51M |
| December 31, 2024 | -60.58M |
| September 30, 2024 | -51.98M |
| June 30, 2024 | -42.70M |
| March 31, 2024 | -52.53M |
| December 31, 2023 | -44.07M |
| September 30, 2023 | -37.97M |
| June 30, 2023 | -32.07M |
| March 31, 2023 | -39.52M |
| December 31, 2022 | -29.41M |
| September 30, 2022 | -34.44M |
| June 30, 2022 | -26.46M |
| March 31, 2022 | -28.33M |
| Date | Value |
|---|---|
| December 31, 2021 | -20.78M |
| September 30, 2021 | -14.11M |
| June 30, 2021 | -12.51M |
| March 31, 2021 | -11.37M |
| December 31, 2020 | -9.366M |
| September 30, 2020 | -10.27M |
| June 30, 2020 | -8.324M |
| March 31, 2020 | -7.893M |
| December 31, 2019 | -8.445M |
| September 30, 2019 | -10.21M |
| June 30, 2019 | -11.34M |
| March 31, 2019 | -11.52M |
| December 31, 2018 | -9.02M |
| September 30, 2018 | -7.575M |
| June 30, 2018 | -7.913M |
| March 31, 2018 | -7.981M |
| December 31, 2017 | -6.516M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Apogee Therapeutics, Inc. | -71.38M |
| Erasca, Inc. | -27.27M |
| Moderna, Inc. | -526.00M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 14.28M |
| Cash from Financing (Quarterly) | 2.955M |
| Free Cash Flow | -309.24M |
| Free Cash Flow Per Share (Quarterly) | -0.4539 |
| Free Cash Flow to Equity (Quarterly) | -83.25M |
| Free Cash Flow to Firm (Quarterly) | -76.42M |
| Free Cash Flow Yield | -5.77% |